Breast Cancer

The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested.

Watch Dr. Naomi Dempsey, from Miami Cancer Institute, discuss the management of HER2-positive, early-stage disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

My cancer diagnosis — and the emotional effects that came with it — made me who I am today.

Watch Dr. Patrick Borgen, from Maimonides Medical Center, discuss the de-escalation of surgery during the CURE Educated Patient® Breast Cancer Summit at MBCC.

I’m reflecting on the distant past — a time before my cancer diagnoses.

Skipping radiation therapy for breast cancer may not affect 10-year survival, but one radiation oncologist suggests patient noncompliance with endocrine therapy is the real reason for reduced benefits.

Watch Dr. Joseph Panoff, from Miami Cancer Institute, Baptist Health South Florida, discuss radiation therapy in early stage disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

The temporary tattoos that guided the radiation for my cancer treatment were not beautiful, artistic or cool — they were more than that.

Watch Dr. Susan Domchek, Dr. Debu Tripathy and Dr. Jennifer Gass answer questions about precision medicine during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. Debu Tripathy, from The University of Texas MD Anderson Cancer Center, discuss circulating tumor DNA during the CURE Educated Patient® Breast Cancer Summit at MBCC.

I’m looking back and sharing the lessons learned from 10 years of cancer survivorship.

Watch Dr. Susan Domchek, from Penn Medicine, discuss genetic testing during the CURE Educated Patient® Breast Cancer Summit at MBCC.

My cancer diagnosis taught me to speak up and ask, “What do I need to know?” and “What can I be doing for myself?”

From Sam Neill announcing his cancer diagnosis to Martina Navratilova stating that she is now cancer-free, here’s what’s happening in the oncology space this week.

Watch Dr. William J Gradishar, Dr. Kevin Kalinsky and Kelly Thomas answer questions about hormone receptor-positive and triple-negative breast cancer treatment options during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Choosing to get a mastectomy was a difficult decision to make, but then the pathology results came back indicating a second cancer.

Patients with HER2-positive breast cancer often need to undergo aggressive treatment, but ongoing research is determining if chemotherapy can be scaled back for certain patients.

Watch Dr. Kevin Kalisnky, from Winship Cancer Institute of Emory University, discuss treatment for triple-negative disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

After being diagnosed with breast cancer, I learned more about the disparities that Black women with the disease face.

As a breast cancer survivor, it’s not only my duty to help the newly diagnosed, but it’s also my responsibility to heed the advice of seasoned champions.

Watch Dr. William J. Gradishar, from Northwestern University, discuss the management of hormone receptor-positive disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Watch Isabel Octaviano, from Miami Cancer Institute, Baptist Health South Florida, discuss the nursing perspective to clinical trials during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.

Exercise, from walking to running, allows patients to take control of their bodies at a time when things may feel out of reach during their cancer journey.